For regulatory approval, the US Food and Drug Administration (FDA) requires evidence of safety and efficacy of new drugs from adequate and well-controlled trials.
1 Improved understanding of the molecular basis of cancer, has led to rapid development of new drugs. In combination with regulatory changes providing rapid review and approval of drugs for diseases with unmet need, 2 this acceleration has led the FDA to use overall response rates (ORRs) assessed in single-arm trials as the basis for approval. Fewer than half of randomized clinical trials (RCTs) supporting FDA approval meet substantial clinical benefit thresholds defined using validated scales such as the European Society of Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). 3 In this study, we applied version 1. Results | Of 134 individual studies supporting new anticancer drug approval, 4 reported subgroup analyses and were evaluated independently. Among these 138 data points, ESMO-MCBS could not be applied to 5 studies. Therefore, 133 data points were included in the analysis. The Table shows differences in study characteristics between approvals supported by RCTs and those supported by single-arm studies. Among all data points, 45 (33.8%) met the criteria for substantial clinical benefit using ESMO-MCBS. For single-arm trials, 2 (7.4%) met the threshold for substantial clinical benefit. These included trials evaluating osimertinib for T790M-mutated nonsmall cell lung cancer and crizotinib for ALK-rearranged non- Discussion | The observation of common and durable response to targeted therapy and immunotherapy has raised questions about whether traditional randomized trials are necessary to support drug approval. 6 The ability to study a drug's ORR, especially in clearly defined target populations, makes the singlearm study design appealing as a pathway to approval. The ability to identify target populations has been aided by increasing understanding of the molecular basis of cancer, which has allowed anatomically defined cancers to be subdivided into smaller, molecularly defined subtypes more likely to respond to targeted therapies. Our data confirm that ORR is a common end point in single-arm studies supporting accelerated approval of anticancer therapies. However, a small proportion of single-arm studies met the threshold for substantial clinical benefit defined by ESMO-MCBS, version 1.1. These results are unsurprising because, to meet substantial benefit thresholds using the ESMO-MCBS, a single-arm trial must show substantial efficacy as well as improvement in quality of life or have data from confirmatory postmarketing study. The low proportion of single-arm trials that meet the threshold for substantial benefit may reflect a lack of supporting data or unrealistic thresholds in the ESMO framework.
In conclusion, approximately one-third of trials supporting FDA drug approval meet the threshold for substantial clinical benefit as measured by ESMO-MCBS. Compared with RCTs, approvals supported by single-arm studies are less likely to show substantial benefit using ESMO-MCBS. It is likely that this reflects the high thresholds for substantial benefit used to calibrate the ESMO-MCBS for single-arm trials.
Opioid Use After Open Resection or Video-Assisted Thoracoscopic Surgery for Early-Stage Lung Cancer
Patients undergoing surgery for early-stage lung cancer often experience persistent postoperative pain; it has been estimated that in 10% of patients the pain can be so intense as to be debilitating. 1 While the current standard of care is to prescribe opioids at discharge, this treatment is intended as shortterm pain control, not to exceed a few weeks after surgery. 
